

Correction

Correction: Okomo-Adhiambo, M. *et al.* Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective. *Viruses* 2010, 2, 2269–2289

Margaret Okomo-Adhiambo ¹, Katrina Sleeman ¹, Kristina Ballenger ¹, Ha T. Nguyen ^{1,2}, Vasiliy P. Mishin ¹, Tiffany G. Sheu ^{1,3}, James Smagala ^{1,4}, Yan Li ⁵, Alexander I. Klimov ¹ and Larisa V. Gubareva ^{1,*}

¹ Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop G16, Atlanta, GA 30333, USA; E-Mails: gfv3@cdc.gov (M.O.-A.); hhk6@cdc.gov (K.S.); isx0@cdc.gov (K.B.); hsn7@cdc.gov (H.T.N.); fwc7@cdc.gov (V.P.M.); gbq3@cdc.gov (T.G.S.); gpa1@cdc.gov (J.S.); axk0@cdc.gov (A.I.K.)

² Atlanta Research and Education Foundation, 1670 Clairmont Rd, 151F, Decatur, GA 30033, USA

³ Battelle, Century Plaza 1, 2987 Clairmont Rd, Suite 450, Atlanta, GA 30329, USA

⁴ Oak Ridge Institute for Science and Education, MC-100-22, P.O. Box 117, Oak Ridge, TN 37831, USA

⁵ Influenza and Respiratory Viruses Section, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington St., Suite H4050, Winnipeg, MB, R3E 3R2, Canada; E-Mail: yan.li@phac-aspc.gc.ca

* Author to whom correspondence should be addressed; E-Mail: lgubareva@cdc.gov; Tel.: +1 404-639-3204; Fax: +1 404-639-0080.

Received: 9 August 2011 / Published: 12 August 2011

The authors would like to make the following corrections to their published paper:

There was an error in calculation of IC₅₀ fold changes for the NAI-resistant viruses reported in Table 1 of the above-mentioned paper. The corrected values are marked in the updated Table 1 below.

Table 1. Reference viruses used as controls in the chemiluminescent NI Assay.

Strain Designation	Type/Subtype	NA Mutations (Genotype)	Oseltamivir Susceptibility	Mean IC ₅₀ ^a ± SD ^b , nM (Fold Difference ^c)		
				Oseltamivir	Zanamivir	Peramivir
A/Washington/10/2008	A (H1N1); Seasonal	WT ^d	S ^e	0.23±0.07 (1)	0.24±0.08 (1)	0.09±0.02 (1)
A/Florida/21/2008	A (H1N1); Seasonal	H275Y	R ^f	94.82±27.04 (386 412)	0.31±0.08 (1)	11.27±1.36 (434 125)
A/Washington/01/2007	A (H3N2); Seasonal	WT	S	0.15±0.00 (1)	0.47±0.04 (1)	0.12±0.02 (1)
A/Texas/12/2007	A (H3N2); Seasonal	E119V	R	4.19±0.33 (30 28)	0.51±0.05 (1)	0.14±0.02 (1)
B/Memphis/20/1996	B; Seasonal	WT	S	1.61±0.21 (1)	1.94±0.21 (1)	0.31±0.06 (1)
B/Memphis/20/1996	B; Seasonal	R152K	R	82.62±2.96 (58 51)	26.35±13.59 (22 14)	52.80±3.51 (476 170)
A/California/07/2009	H1N1; Pandemic	WT	S	0.21±0.03 (1)	0.26±0.04 (1)	0.06±0.02 (1)
A/Texas/48/2009	H1N1; Pandemic	H275Y	R	79.94±0.06 (348 381)	0.36±0.07 (1)	10.06±0.01 (464 168)

^a Average of 3 independent assays. ^b SD, Standard Deviation of IC₅₀ values. ^c Fold difference in IC₅₀ values between mutant and wildtype viruses, by drug and virus type/subtype (IC₅₀ of mutant/IC₅₀ of wildtype virus). ^d WT, Wildtype. ^e S, Sensitive (Susceptible). ^f R, Resistant.

We apologize for any inconvenience caused to the readers.

© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).